Simulations Plus, Inc.

Business Insights

Simulations Plus, Inc. | July 04, 2022

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record-setting attendance and virtual content delivery for the 2022 Pharmacometrics Spring School using MonolixSuite™. New for 2022 was the introduction of the “NCA, bioequivalence, and beyond! Spring School” course using PKanalix™. Both workshops were held in March 2022. This year’s Spring Schools fo...

Business Insights

Simulations Plus, Inc. | August 08, 2022

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced it has entered a new collaboration with a large pharmaceutical company to extend the industry’s top-rated machine learning models for the prediction of ionization constants (pKa) in the ADMET Predictor® platform. In this collaboration, the partner company will contribute tens of thousands of proprietary pKa measurements. The t...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Public News Service | January 14, 2020

The skyrocketing cost of prescription drugs has become a bipartisan issue among voters, and Utahns overwhelmingly back a plan to help diabetics overcome the cost of life-saving insulin. A new poll from UtahPolicy.com Y-2 Analytics finds 4 out of 5 registered voters would support legislation to cap out-of-pocket costs for insulin. The idea mirrors a bill passed in Colorado in 2019 to limit a patient's out-of-pocket costs for insulin, a hormone critical to diabetics for controlling their blood...